 Home > Medical News > Latest Medical News > Xinlitai HFpEF drug SAL007 clinical trial application accepted

Xinlitai HFpEF drug SAL007 clinical trial application accepted

 Last Update: 2022-05-19
 Source: Internet
 Author: User

Tags

plasma phase

electricity united states

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 19, Xinlitai announced that the clinical trial application of the drug recombinant human neuregulin 1-anti-HER3 antibody fusion protein injection (domestic project code: SAL007) has been accepted

SAL007 (US project code: JK07, hereinafter referred to as "07") is an NRG-1 (neuregulin-1) fusion antibody drug independently developed by Salubris Bio in the United States and has global intellectual property rights.

This product is the company's first innovative biological drug that is reported in both China and the United States.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.